James Wilbur Biography and Net Worth

Insider of 10x Genomics

Jim Wilbur joined 10x Genomics as Chief Commercial Officer in July 2022. In this role, Jim is responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.

A life sciences entrepreneur and seasoned global commercial executive, Jim has nearly 30 years of experience building businesses, developing high-performance teams and scaling commercial organizations to drive growth and customer success.

He served as Chief Business Officer and General Manager of Meso Scale Discovery ("MSD") until July 2022. He worked at MSD or its affiliates since its inception in 1995, holding a variety of technical and commercial roles of increasing responsibility. Jim led the commercial functions of MSD from September 2001, when MSD launched its first products, to July 2022.

Prior to joining MSD, he was a National Institutes of Health Postdoctoral Fellow at Harvard University. Jim holds a B.A. degree in Chemistry and Intellectual History from the University of California, San Diego, and a Ph.D. in Chemistry from Stanford University.

What is James Wilbur's net worth?: The estimated net worth of James Wilbur is at least $1.17 million as of November 22nd, 2023. Mr. Wilbur owns 83,342 shares of 10x Genomics stock worth more than $1,170,122 as of December 20th. This net worth evaluation does not reflect any other assets that Mr. Wilbur may own. Learn More about James Wilbur's net worth.
How do I contact James Wilbur?: The corporate mailing address for Mr. Wilbur and other 10x Genomics executives is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. 10x Genomics can also be reached via phone at 925-401-7300 and via email at [email protected]. Learn More on James Wilbur's contact information.
Has James Wilbur been buying or selling shares of 10x Genomics?: James Wilbur has not been actively trading shares of 10x Genomics within the last three months. Most recently, James Wilbur sold 3,464 shares of the business's stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $43.34, for a transaction totalling $150,129.76. Following the completion of the sale, the insider now directly owns 83,342 shares of the company's stock, valued at $3,612,042.28. Learn More on James Wilbur's trading history.
Who are 10x Genomics' active insiders?: 10x Genomics' insider roster includes Bradford Crutchfield (Insider), Benjamin Hindson (Insider), Sridhar Kosaraju (Director), Mathai Mammen (Director), Justin McAnear (CFO), Serge Saxonov (CEO), John Stuelpnagel (Director), and James Wilbur (Insider). Learn More on 10x Genomics' active insiders.
Are insiders buying or selling shares of 10x Genomics?: During the last year, insiders at the sold shares 12 times. They sold a total of 42,920 shares worth more than $1,379,729.99. The most recent insider tranaction occured on August, 22nd when CEO Serge Saxonov sold 6,749 shares worth more than $152,054.97. Insiders at 10x Genomics own 10.0% of the company. Learn More about insider trades at 10x Genomics.
Information on this page was last updated on 8/22/2024.

James Wilbur Insider Trading History at 10x Genomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/22/2023	Sell	3,464	$43.34	$150,129.76	83,342
11/20/2023	Sell	14,718	$42.09	$619,480.62	86,806
8/22/2023	Sell	9,699	$45.78	$444,020.22	101,253

James Wilbur Buying and Selling Activity at 10x Genomics

10x Genomics Company Overview

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Today's Range

Now: $14.04

$13.41

$14.44

50 Day Range

MA: $15.29

$13.18

$17.34

2 Week Range

Now: $14.04

$12.95

$57.78

Volume

2,024,544 shs

Average Volume

1,750,978 shs

Market Capitalization

$1.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.